UBS sets USD 155.00 target for Encompass Health stock
Published on 10/15/2026 at 19:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and timing
- UBS analyst A.J. Rice set a USD 155.00 target on October 13, 2026.
- Encompass Health will report third-quarter results on October 28, 2026.
- Encompass Health stock costs EUR 114.50 at Lang & Schwarz on October 15, 2026 at 7:00 p.m. CEST, while NYSE EHC is up 1.46 percent on the day.
- Encompass Health has a USD 12.7 billion market capitalization as of October 15, 2026.
UBS analyst A.J. Rice maintained a Buy rating on Encompass Health and set a USD 155.00 price target on October 13, 2026, according to Markets Insider. The target is 20.71 percent above the NYSE price of USD 128.41 on October 15, 2026. Encompass Health was trading at EUR 114.50 at Lang & Schwarz on October 15, 2026 at 7:00 p.m. CEST.
Results arrive October 28
Encompass Health will report third-quarter results after the market close on October 28, 2026, and hold its earnings call on October 29, 2026. The date was announced in an October 1, 2026 release from Encompass Health.
In the second quarter of 2026, revenue reached USD 1.60 billion and earnings per share came to USD 1.55, up from USD 1.40 a year earlier. Revenue increased 9.60 percent year over year, while the company set full-year 2026 earnings-per-share guidance at USD 6.02 to USD 6.25, according to MarketBeat.
NYSE price nears the yearly high
On the NYSE, Encompass Health stood at USD 128.41 at 1:04 p.m. ET on October 15, 2026, up 1.46 percent from USD 126.56. The 52-week range was USD 92.77 to USD 129.96, placing the stock 1.19 percent below its high. Trading volume was 462,688 shares against an average of 897,829.
Valuation and peers
Encompass Health had a USD 12.7 billion market capitalization, a price-to-earnings ratio of 20.93 and a dividend yield of 1.00 percent as of October 15, 2026. UBS provides the clearest dated target in the latest coverage, while the October 28 reporting date is the next scheduled company event.
Comparison with peers
EHC (NYSE, USD): plus 1.46 percent, P/E 20.93, market capitalization USD 12.7 billion
HCA (NYSE, USD): minus 0.38 percent, P/E 15.69, market capitalization USD 101.5 billion
UHS (NYSE, USD): plus 1.08 percent, P/E 7.71, market capitalization USD 11.1 billion
Price stays near the upper range
The euro quotation remains close to its latest Lang & Schwarz level, while the NYSE price is 1.19 percent below the 52-week high. The next reported period will test whether the 9.60 percent second-quarter revenue growth can continue.
The further course of trading is shown by the continuously updated real-time quote of Encompass Health stock.
Encompass Health market facts
- Company: Encompass Health Corporation
- ISIN: US29261A1007
- Ticker: EHC
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 15, 2026, 7:00 p.m. CEST): EUR 114.50
- Market capitalization: USD 12.7 billion (as of October 15, 2026)
- NYSE 52-week range: USD 92.77-129.96 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical - Care Facilities
Market context: Market report S&P 500.
